Cobimetinib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Cobimetinib: From BRAF V600-Mutant Melanoma to Amyotrophic Lateral Sclerosis
One-Sentence Summary
Cobimetinib was originally used, in combination with vemurafenib, to treat unresectable or metastatic melanoma with a BRAF V600 mutation. The TxGNN model predicts it may be effective for amyotrophic lateral sclerosis (ALS), but there are currently 0 clinical trials and 0 publications supporting this direction. The prediction rests on a computational score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Use in combination with vemurafenib for adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation |
| Predicted New Indication | Amyotrophic lateral sclerosis |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L5 |
| EU Market Status | Cancelled only (the single authorization has been cancelled) |
| Number of Authorizations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, cobimetinib is a MEK1/2 inhibitor that blocks the MAPK/ERK signalling pathway. Its efficacy in BRAF V600-mutant melanoma, where it is combined with the BRAF inhibitor vemurafenib, has been established.
MAPK/ERK pathway activation has been implicated in neuroinflammation and motor neuron stress responses in ALS models. This offers a plausible but unvalidated rationale for the prediction. Melanoma and ALS are very different diseases, and no direct similarity between the original and new indication has been established.
Important caveats:
- The TxGNN score is very high (0.997), but it is a computational prediction only.
- Brain penetration is a concern, because cobimetinib is thought to be a P-glycoprotein substrate. This has not been assessed here.
- Other top predictions are mostly rare motor neuron or genetic disorders (e.g., Mills syndrome, monomelic amyotrophy, ALS type 22). They share the same speculative rationale and are likely correlated with the ALS prediction. Several others (e.g., polymicrogyria, axial spondylometaphyseal dysplasia) have no supported mechanistic link.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| EMEA/H/C/003960 (cancelled) | Cotellic | Not specified | Use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (MEK inhibitor) |
| Myelosuppression Risk | Please refer to the SmPC warnings and precautions |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Please refer to the SmPC warnings and precautions |
| Handling Protection | Please refer to the SmPC warnings and precautions |
Safety Considerations
- Drug Interactions: The data compiled for this report list 266 interacting drugs. Examples of major interactions include:
- Aprepitant
- Dexamethasone
- Clarithromycin
- Cobicistat
- Samarium (153Sm) lexidronam
Examples of moderate interactions include cimetidine, clotrimazole, miconazole, naltrexone, rolapitant, ticagrelor, quinine and ivacaftor.
- Class-related concerns noted in the predictions: MEK inhibitors carry known ocular toxicity (e.g., serous retinopathy). Other toxicities of concern include dermatologic, hepatic and cardiac effects. These matter especially for any proposed use in retinal or benign, self-limiting conditions.
Please refer to the SmPC for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The ALS prediction has a very high model score but no registered trials, no literature and only a speculative mechanistic link (L5). The only EU authorization has been cancelled, and brain penetration and the toxicity profile raise concerns for a chronic neurodegenerative indication.
To proceed, the following is needed:
- Preclinical evidence that MEK inhibition is beneficial in ALS models
- Assessment of central nervous system penetration, including P-gp efflux
- Detailed mechanism of action data
- Warnings and contraindications from the SmPC, to support safety screening
- A risk-benefit assessment for long-term use in ALS, considering ocular, dermatologic, hepatic and cardiac toxicity
- Clarification of the cancelled EU authorization status and of the product’s availability
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.